Surrozen, Inc./DE

Surrozen, Inc. announced that its management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The presentation will be a fireside chat held on Tuesday, May 19, 2026, at 11:30 AM Eastern Time. Interested parties can access a live audio webcast and a replay on the company's investor relations website.

Surrozen reported a net loss of $(127.5) million for Q1 2026, a significant increase from $(27.0) million in Q1 2025, primarily driven by non-cash changes in the fair value of tranche and warrant liabilities. The company generated $5.0 million in collaboration and license revenue from a research milestone achieved with Boehringer Ingelheim. Surrozen ended the quarter with $106.9 million in cash and cash equivalents, having raised $26.9 million through its At-the-Market (ATM) program.

Surrozen, Inc. reported a net loss of $127.5 million for the first quarter ended March 31, 2026, significantly higher than the $27.0 million loss in Q1 2025. Despite the increased loss, the company's cash and cash equivalents rose to $106.9 million, partly due to a $5.0 million milestone payment from Boehringer Ingelheim. Surrozen also announced it remains on track to submit an Investigational New Drug (IND) application for its lead candidate SZN-8141 in the second half of 2026, following positive preclinical efficacy data presentations.

Surrozen, Inc. announced the grant of non-statutory stock options for 2,020 shares of its common stock to a recently hired non-executive employee. This grant, made on April 24, 2026, serves as an inducement for employment and was approved by the Compensation Committee under the company's 2025 Equity Inducement Plan. The options allow for the purchase of shares at $28.14 each and vest over a four-year period, with initial vesting after one year.